Skip to page content
  • TMEM16A inhibitors as a treatment option for cystic fibrosis

    B78025

    TMEM16A inhibitors as a treatment option for cystic fibrosis

    • TMEM16A inhibitors represent a causal treatment for cystic fibrosis
    • They reduce both excessive mucus formation and airway contraction
    • Repurposing possible: TMEM16A inhibitors include FDA-approved and well-tolerated drugs

1 of 99 Tech Offer

Interested? Get in touch!

Contact a specific team member via the Team section or simply use our contact form for your request.

Privacy settings

This website uses cookies. Cookies improve its usage and help make this website better.
Privacy policy